AbbVie Showcases Next-Generation ADC and T-Cell Engager Data at ASCO 2026
核心洞察
AbbVie (搜索) presented promising data from its novel Topoisomerase I inhibitor-based ADC platform at ASCO 2026, with ABBV-969 achieving a 45% objective response rate in heavily pretreated metastatic castration-resistant prostate cancer (搜索) patients.
The company's SEZ6 (搜索)-directed ADC ABBV-706 demonstrated an 82% objective response rate as second-line therapy in small cell lung cancer (搜索) patients, showing potential in a disease with poor prognosis.
Etentamig, a next-generation BCMA (搜索) x CD3 (搜索) T-cell engager, achieved a 64% objective response rate in heavily pre-treated multiple myeloma (搜索) patients previously exposed to BCMA-directed CAR-T therapy.
AbbVie (搜索) announced comprehensive data from its next-generation oncology pipeline at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating significant progress across its antibody-drug conjugate (ADC) and T-cell engager platforms. The presentations span multiple cancer types, including solid tumors and blood cancers, highlighting the company's strategy of attacking cancer from inside and outside the cell.
Breakthrough Results in Prostate Cancer
The company's most notable advancement comes from ABBV-969, a potential first-in-class bispecific ADC targeting PSMA (搜索)/STEAP1 (搜索). In a first-in-human Phase 1 study (NCT06318273) evaluating heavily pretreated patients with metastatic castration-resistant prostate cancer (搜索) (mCRPC), ABBV-969 demonstrated a confirmed objective response rate (ORR) of 45% among 29 patients with RECIST-evaluable disease.
At active dose levels, 67% of patients achieved at least a 50% reduction in prostate-specific antigen (PSA50), with 28% achieving PSA90 responses. The safety profile was manageable in this heavily pretreated patient population, supporting continued development of this novel bispecific approach.
Small Cell Lung Cancer Shows Promise
ABBV-706, a SEZ6 (搜索)-directed ADC, delivered particularly encouraging results in small cell lung cancer (搜索) (SCLC), a disease where prognosis remains poor. In Phase 1 data (NCT05599984) from the monotherapy cohort (n=17), SCLC patients receiving ABBV-706 at the recommended Phase 3 dose of 1.8 mg/kg as second-line therapy achieved an objective response rate of 82%.
The safety profile was comparable with previously reported data, and the findings support continued evaluation of ABBV-706 in SCLC, representing a potential breakthrough in this challenging indication.
Expanding Solid Tumor Applications
Telisotuzumab adizutecan (Temab-A), a next-generation c-Met (搜索)-directed ADC, demonstrated antitumor activity in biomarker unselected platinum-resistant ovarian cancer (搜索) (PROC) and head and neck squamous cell carcinoma (搜索) (HNSCC) patients in Phase 1 basket studies (NCT06084481). Additional observations in c-Met selected patients highlight the potential of Temab-A across an expanding range of solid tumors and patient populations.
These new data support the potential of Temab-A across previously presented indications including lung, colorectal and gastric cancers, particularly in patients with MET-amplification and increased c-Met (搜索) expression.
Next-Generation T-Cell Engager Success
In the blood cancer space, etentamig, being investigated as a next-generation B-cell maturation antigen (BCMA (搜索)) x CD3 (搜索) T-cell engager, showed promising activity in heavily pre-treated patients. The Phase 1b study (NCT05650632) focused on a challenging cohort of relapsed/refractory multiple myeloma (搜索) (R/R MM) patients with prior BCMA exposure.
Among patients (n=11) who proceeded to etentamig after BCMA (搜索)-directed CAR-T in the prior line of therapy, an ORR of 64% was achieved. Minimal residual disease (MRD) negativity was observed in 67% (2/3) of evaluable patients who received BCMA-directed therapy in the prior line of therapy, with a median duration of response of 13 months.
Notably, despite no step-up dosing in this cohort, all cytokine release syndrome (CRS) reported (57%) were grade 1 and 2, with no new safety signals observed. Etentamig is composed of bivalent BCMA (搜索)-binding domains allowing for high BCMA-avidity and a low-affinity CD3 (搜索) binding domain.
Strategic Pipeline Approach
"Our oncology pipeline is intentionally designed to address the complexity and heterogeneity of cancer biology through a diversified portfolio of differentiated therapies spanning multiple modalities," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie (搜索).
The data presented at ASCO reflect AbbVie (搜索)'s sustained investment in its expanding ADC platform, including Topoisomerase I inhibitor (Top1i)-based ADCs and its T-cell engager portfolio. The company is currently evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers.
All presented compounds—Telisotuzumab adizutecan (Temab-A), etentamig, ABBV-969, and ABBV-706—are investigational medicines not approved by any health authorities worldwide, with safety and efficacy under evaluation in ongoing clinical studies.